Hubei Goto Biopharm Co.,Ltd.

SZSE:300966 Stock Report

Market Cap: CN¥2.2b

Hubei Goto BiopharmLtd Past Earnings Performance

Past criteria checks 0/6

Hubei Goto BiopharmLtd's earnings have been declining at an average annual rate of -38.9%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 2% per year.

Key information

-38.9%

Earnings growth rate

-45.2%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate2.0%
Return on equity-1.6%
Net Margin-2.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Hubei Goto BiopharmLtd's (SZSE:300966) Soft Earnings Are Actually Better Than They Appear

May 02
Hubei Goto BiopharmLtd's (SZSE:300966) Soft Earnings Are Actually Better Than They Appear

Recent updates

Hubei Goto Biopharm Co.,Ltd. (SZSE:300966) Shares Fly 42% But Investors Aren't Buying For Growth

Oct 09
Hubei Goto Biopharm Co.,Ltd. (SZSE:300966) Shares Fly 42% But Investors Aren't Buying For Growth

Hubei Goto Biopharm Co.,Ltd. (SZSE:300966) Held Back By Insufficient Growth Even After Shares Climb 26%

May 12
Hubei Goto Biopharm Co.,Ltd. (SZSE:300966) Held Back By Insufficient Growth Even After Shares Climb 26%

Hubei Goto BiopharmLtd's (SZSE:300966) Soft Earnings Are Actually Better Than They Appear

May 02
Hubei Goto BiopharmLtd's (SZSE:300966) Soft Earnings Are Actually Better Than They Appear

Lacklustre Performance Is Driving Hubei Goto Biopharm Co.,Ltd.'s (SZSE:300966) Low P/S

Feb 28
Lacklustre Performance Is Driving Hubei Goto Biopharm Co.,Ltd.'s (SZSE:300966) Low P/S

Revenue & Expenses Breakdown

How Hubei Goto BiopharmLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:300966 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24547-146240
30 Jun 2453206137
31 Mar 24569235637
31 Dec 23566235538
30 Sep 23543235446
30 Jun 23604315049
31 Mar 23604314947
01 Jan 23605404745
30 Sep 22592643942
30 Jun 22557644141
31 Mar 22570764139
01 Jan 22591784137
30 Sep 21595763635
30 Jun 21569762928
31 Mar 21573712726
31 Dec 20468532122
31 Dec 19465732326
31 Dec 18437711727
31 Dec 17334471923

Quality Earnings: 300966 is currently unprofitable.

Growing Profit Margin: 300966 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300966 is unprofitable, and losses have increased over the past 5 years at a rate of 38.9% per year.

Accelerating Growth: Unable to compare 300966's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 300966 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).


Return on Equity

High ROE: 300966 has a negative Return on Equity (-1.61%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies